Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Frequently asked questions
What sector does Anebulo Pharmaceuticals Inc (ANEB) operate in?
Anebulo Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Anebulo Pharmaceuticals Inc (ANEB) current stock price?
As of the latest data, Anebulo Pharmaceuticals Inc stock price is $0.30, with a previous close of $0.33. Anebulo Pharmaceuticals Inc lost -$0.03 in the last trading session, representing a -7.88% loss.
What is Anebulo Pharmaceuticals Inc (ANEB) current market capitalization?
Anebulo Pharmaceuticals Inc market cap is approximately 12.40 million.
What is Anebulo Pharmaceuticals Inc (ANEB) Earnings Per Share (EPS)?
The trailing EPS is -$0.18, and the forward EPS is -$0.46.
Does Anebulo Pharmaceuticals Inc (ANEB) pay dividends?
No. Anebulo Pharmaceuticals Inc does not pay a dividend.
What is Anebulo Pharmaceuticals Inc (ANEB) beta (volatility) score?
Anebulo Pharmaceuticals Inc has a beta of -1.838, indicating lower volatility than the overall market.
